This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the metastatic setting. Electronic medical record (EMR) data of patients with 1L sunitinib or sorafenib monotherapy will be screened from Grade-A Tertiary hospitals in China. The study period is from 1st September 2007 to 31st December 2024.
Age ≥ 18 years at the index date
Patients with papillary urothelial carcinoma or renal pelvis cancer of the kidney;
Patients with history of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years;
Patients with missing both day and month of index date;
Patients with severe conditions that are greater or equal to grade 3 by the definition of CTCAE 5.0 criteria when included into the study;